The FTD trial delay signals a narrower near-term pipeline catalyst, but the OLE launch and maintained cash runway reduce dilution risk. Watch for topline data from the ALSTARS double-blind phase, which is the next major binary catalyst.
Price Chart
Executive Summary
Coya Therapeutics announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial for COYA 302 in ALS, starting November 2026. Concurrently, the company is delaying the planned Phase 2 trial for COYA 302 in frontotemporal dementia (FTD) from H2 2026 to 2027, citing resource prioritization toward the ALS program. Cash runway guidance remains unchanged, funding operations into H2 2027.
Key Facts
- Open-label extension (OLE) of Phase 2/3 ALSTARS trial for COYA 302 in ALS expected to begin November 2026.
- Initiation of Phase 2 trial for COYA 302 in frontotemporal dementia (FTD) delayed from H2 2026 to 2027.
- Cash runway unchanged: existing resources expected to fund operations into H2 2027.
- ALSTARS trial is a randomized, double-blind, placebo-controlled study with ~120 subjects and a 48-week treatment period.
Financial Impact
No financial figures provided; cash runway unchanged, funding into H2 2027.
Risk Factors
- FTD trial delay may disappoint investors expecting a broader pipeline timeline.
- ALSTARS topline data readout remains the primary risk/reward event; negative results would be material.
- Pre-revenue clinical-stage biotech with no approved products — cash burn and dilution risk persist.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-421066 |
| Document: 0001193125-26-421066-index-headers.html | 0001193125-26-421066 |
| Document: 0001193125-26-421066-index.html | 0001193125-26-421066 |
| Document: 0001193125-26-421066.txt | 0001193125-26-421066 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $4.18 | awaiting T+20 | — | $4.17 (−0.24%) |
Oct 5, 2026 22d ago | 8-K | $4.85 | awaiting T+20 | — | $4.17 (−14.02%) |
Sep 15, 2026 6w ago | 8-K | $4.65 $4.48 | ▼ −3.76% | ▼ −6.74% | $4.17 (−10.32%) |
Aug 11, 2026 11w ago | 8-K | $4.80 $4.61 | ▼ −3.96% | ▼ −2.90% | $4.17 (−13.12%) |
May 12, 2026 24w ago | 8-K | $4.29 $4.41 | ▲ +2.80% | ▲ +4.52% | $4.17 (−2.80%) |
Apr 2, 2026 29w ago | 8-K | $4.01 $4.23 | ▲ +5.49% | ▼ −4.39% | $4.17 (+3.99%) |
Mar 23, 2026 31w ago | EFFECT | $4.22 $4.53 | ▲ +7.35% | ▼ −0.07% | $4.17 (−1.18%) |
Mar 16, 2026 32w ago | S-3 | $4.50 $4.46 | ▼ −0.89% | ▼ −4.67% | $4.17 (−7.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers